Tracheal stenosis is a benign acquired iatrogenic disease. It may follow prolonged orotracheal intubation and tracheostomy, and individuals will often experience dyspnea, stridor, phonation ablation, dysphonia and dysphagia (1-3). Despite improvements in technology such as low cuff pressure and percutaneous dilation tracheostomy (PDT) approaches, tracheal stenosis continues to be a major burden (4). Studies have suggested that some degree of stenosis develops in up to 20% to 30% of patients with tracheostomy, and 1% to 7% of patients develop symptoms with the need for invasive procedures (4,5). This results in frequent visits to emergency department (ED), increased health-care costs and reduced health-related quality of life for the patients.

A recent study (5) analyzed a cross-sectional analysis of U.S. ED visits, hospital discharges, and readmissions using the 2013 National Emergency Department Sample, 2013 National Inpatient Sample, and 2013 Nationwide Readmission Database for patients with tracheal stenosis due to tracheostomies. Furthermore, patients that were readmitted within the same calendar year with tracheal stenosis due to the tracheostomy cannula were also queried. There were an estimated 6,156 ED visits; 4,920 hospital discharges; and 2,316 readmissions for tracheal stenosis due to tracheostomies in 2013. Among 71,446 tracheostomies, 739 (1.05%) were readmitted with tracheal stenosis after the initial admission. Tracheal stenosis due to tracheostomy represented 28.0% of all tracheostomy complication-related ED visits. The median ED charges were US$1,682 (IQR, $932–2,920). The median length of stay was 8 days (IQR, 4–19 days). The median total charges for the inpatient stay was US$66,416 (IQR, $29,770–182,779). The in-hospital mortality was 3.2% (95% CI, 2.4–4.3%). Among the new tracheostomy patients who were readmitted with tracheal stenosis, the median length of stay was 36 days (IQR, 23–66 days). The median inpatient charges were $390,187 (IQR, $239,943–$659,784), and the in-hospital mortality was 22.8% (95% CI, 18.0–28.6%).

Spataro et al. (6) performed a prospective single-center analysis to evaluate tracheostomy inpatient and outpatient complication rates, determine the 30-day all-cause and tracheostomy-related readmission rates and to assess patient and procedural risk factors associated with complications and readmissions. Of the 100 patients included, 47% experienced an inpatient tracheostomy-related complication. Thirty-five percent experienced some harm, defined as Clavien-Dindo grade II or higher; and 13% experienced severe harm (grade III or higher). Fifteen percent experienced an outpatient complication, and 33% were readmitted to the hospital for any cause within 30 days of discharge. Of the 29 patients readmitted to the hospital, 11 (38% of all readmissions) were due to tracheostomy-specific causes. The overall 30-day all-cause hospital readmission rate was 33% and the tracheostomy-specific readmission rate was 13%. There was one tracheostomy-related death.

Moreover, the costs associated with tracheal injuries are also overwhelming. Bhatti and colleagues (7) performed a cost-analysis using the AHRQ 2006 National Inpatient Sample, and compared patients with tracheal injury coded during the medical or surgical stay for length of stay (LOS) and mean hospital cost with diagnosis-related matched...
controls. A total of 3,232 discharge records met criteria for tracheal injury from within the index hospital stay. Average LOS for patients with tracheal injury (6.3 days) exceeded LOS in the uncomplicated sample (5.2 days) by 1.1 days. The average hospital cost was US$ 1888 higher with tracheal injury [$10,375 (CI, $9,762–10,988) vs. $8,487 (CI, $8,266–8,669)]. LOS for procedures treating prior tracheal injury averaged 4.7 days and cost an average of $11,025 per discharge.

We can conclude that tracheal injuries, stenosis and tracheostomies are devastating conditions. They have high morbidity, mortality and are extremely costly to the healthcare system.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Translational Cancer Research for the series “Recent Developments in Benign Tracheal Stenosis”. The article did not undergo external peer review.

Conflicts of Interest: The series “Recent Developments in Benign Tracheal Stenosis” was commissioned by the editorial office without any funding or sponsorship. BJB, PFGC and KH served as the unpaid Guest Editors of the series.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The authors have no other conflicts of interest to declare.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References


Cite this article as: Bibas BJ, Cardoso PFG, Hoetzenecker K. The burden of tracheal stenosis and tracheal diseases healthcare costs in the 21st century. Transl Cancer Res 2020;9(3):2095-2096. doi: 10.21037/tcr.2020.02.59